Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.46 +0.8%	$2.76	$2.06 ▼ $25.02	$7.13M	-0.32	670,340 shs	50,927 shs
APLM Apollomics	$6.23 +0.5%	$6.04	$4.47 ▼ $35.98	$6.87M	0.92	23,268 shs	2,852 shs
ATXI Avenue Therapeutics	$0.58 -0.3%	$0.40	$0.17 ▼ $3.54	$1.84M	N/A	172,123 shs	345 shs
SBFM Sunshine Biopharma	$1.48 +2.1%	$1.49	$1.17 ▼ $3.90	$6.74M	1.45	615,097 shs	72,191 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+0.83%	+4.27%	-17.57%	-26.51%	-90.49%
APLM Apollomics	-4.27%	+12.20%	-2.73%	-8.87%	-57.32%
ATXI Avenue Therapeutics	-0.34%	+8.24%	+45.52%	+122.39%	-79.21%
SBFM Sunshine Biopharma	+3.57%	+2.11%	-7.05%	+0.69%	-50.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.9046 of 5 stars	3.5	2.0	0.0	2.4	3.3	0.6
APLM Apollomics	0.386 of 5 stars	0.0	3.0	0.0	3.3	0.0	0.0
ATXI Avenue Therapeutics	2.3707 of 5 stars	0.0	3.0	4.6	2.8	0.0	1.9
SBFM Sunshine Biopharma	3.0277 of 5 stars	3.5	3.0	0.0	4.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$45.00	1,729.27% Upside
APLM Apollomics	0.00	N/A	N/A	N/A
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
SBFM Sunshine Biopharma	3.00	Buy	$15.00	913.51% Upside

Current Analyst Ratings Breakdown

Latest ATXI, ALZN, SBFM, and APLM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	ALZN Alzamend Neuro	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $45.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	$4.48 per share	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
SBFM Sunshine Biopharma	$36.34M	0.19	N/A	N/A	$5.63 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
APLM Apollomics	-$53.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	-$10.38M	-$0.95	0.03	∞	N/A	N/A	-471.57%	-296.50%	11/12/2025 (Estimated)
SBFM Sunshine Biopharma	-$5.13M	-$150.88	N/A	∞	N/A	-17.35%	-26.04%	-20.72%	11/3/2025 (Estimated)

Latest ATXI, ALZN, SBFM, and APLM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SBFM Sunshine Biopharma	-$0.11	-$0.39	-$0.28	-$0.39	$12.10 million	$9.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
SBFM Sunshine Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
APLM Apollomics	N/A	1.39	1.39
ATXI Avenue Therapeutics	N/A	2.70	2.70
SBFM Sunshine Biopharma	N/A	5.00	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
APLM Apollomics	19.13%
ATXI Avenue Therapeutics	17.34%
SBFM Sunshine Biopharma	41.98%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
APLM Apollomics	N/A
ATXI Avenue Therapeutics	1.80%
SBFM Sunshine Biopharma	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
APLM Apollomics	45	1.10 million	N/A	Not Optionable
ATXI Avenue Therapeutics	4	3.18 million	2.02 million	Not Optionable
SBFM Sunshine Biopharma	3	4.56 million	4.55 million	Not Optionable

ATXI, ALZN, SBFM, and APLM Headlines

Recent News About These Companies

Sunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - Morningstar

July 3, 2025 | morningstar.comM

SBFM - Sunshine Biopharma Inc News - Morningstar

July 3, 2025 | morningstar.comM

Sunshine Biopharma, Inc. (SBFM) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

July 2, 2025 | accessnewswire.comA

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

June 11, 2025 | msn.com

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

June 11, 2025 | accessnewswire.comA

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025 | finanznachrichten.de

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025 | accessnewswire.comA

Sunshine Biopharma launches Everolimus in Canada

April 22, 2025 | markets.businessinsider.com

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

April 21, 2025 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

April 3, 2025 | accessnewswire.comA

This Pharma Stock Is Gaining Major Steam Ahead Of Opening Bell

April 2, 2025 | msn.com

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

April 2, 2025 | accessnewswire.comA

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

April 2, 2025 | benzinga.com

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

April 2, 2025 | finance.yahoo.com

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

April 1, 2025 | accessnewswire.comA

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

March 24, 2025 | msn.com

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

March 24, 2025 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

March 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI, ALZN, SBFM, and APLM Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.46 +0.02 (+0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.43 -0.03 (-1.22%)

As of 05:18 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Apollomics NASDAQ:APLM

$6.23 +0.03 (+0.48%)

Closing price 03:55 PM Eastern

Extended Trading

$6.37 +0.14 (+2.25%)

As of 05:52 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Avenue Therapeutics NASDAQ:ATXI

$0.58 0.00 (-0.34%)

As of 11:17 AM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Sunshine Biopharma NASDAQ:SBFM

$1.48 +0.03 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.02 (+1.69%)

As of 05:56 PM Eastern

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time